Inhibition of uric acid or IL-1β ameliorates respiratory syncytial virus immunopathology and development of asthma.

Charles F SchulerCarrie-Anne MalinczakShannon K K BestSusan B MorrisAndrew J RaskyCatherine PtaschinskiNicholas W LukacsWendy Fonseca

Published in: Allergy (2020)

Inhibiting UA and IL-1β during RSV infection ameliorates RSV immunopathology, reduces the consequences of allergen-induced asthma, and presents new therapeutic targets to reduce early-life viral-induced asthma development.

Keyphrases

respiratory syncytial virus
uric acid
early life
chronic obstructive pulmonary disease
allergic rhinitis
lung function
high glucose
diabetic rats
metabolic syndrome
mouse model
sars cov
drug induced
signaling pathway
endothelial cells